M
IMEPro
M72.2 Musculoskeletal
Updated March 2026

Plantar fascial fibromatosis (plantar fasciitis)

ICD-10 Code: M72.2 · Body Part: Ankle/Foot

QME Evaluation Process

Foot examination, palpation of plantar fascia, gait analysis, imaging review. LE impairment based on hindfoot/midfoot ROM and gait abnormality.

Typical Impairment Rating

3-7% LE (1-3% WPI)

AMA Guides Edition

5th Edition

Common Treatments

+ Orthotics
+ Physical therapy
+ Corticosteroid injection
+ PRP injection
+ Plantar fascia release

Related Conditions

Body Part Guide

Ankle/Foot Evaluation Guide

Impairment rating methods, common conditions, and QME evaluation protocols

View Guide →

QME Specialties for Plantar fascial fibromatosis (plantar fasciitis)

Find a QME Specialist

Browse QME-certified physicians who evaluate plantar fascial fibromatosis (plantar fasciitis) and related ankle/foot conditions in California.

Browse Physical Medicine & Rehabilitation Physicians →

Frequently Asked Questions

What is Plantar fascial fibromatosis (plantar fasciitis) (M72.2)?

Plantar fascial fibromatosis (plantar fasciitis) is an ICD-10 diagnosis code (M72.2) classified under Musculoskeletal conditions. It affects the Ankle/Foot and is commonly encountered in California workers' compensation claims. QME physicians evaluate this condition using AMA Guides 5th Edition protocols.

How is M72.2 rated for impairment?

The typical whole person impairment (WPI) range for Plantar fascial fibromatosis (plantar fasciitis) is 3-7% LE (1-3% WPI). The exact rating depends on clinical findings, imaging, and the evaluation method (DRE or ROM) chosen by the QME physician per AMA Guides 5th Edition.

What is the QME evaluation process for M72.2?

Foot examination, palpation of plantar fascia, gait analysis, imaging review. LE impairment based on hindfoot/midfoot ROM and gait abnormality.

What treatments are common for Plantar fascial fibromatosis (plantar fasciitis)?

Common treatments for Plantar fascial fibromatosis (plantar fasciitis) include Orthotics, Physical therapy, Corticosteroid injection, PRP injection, Plantar fascia release. Treatment appropriateness and outcomes are considered during the QME evaluation when determining permanent and stationary status and apportionment.